GermanyGermany

BASF Plant Science says goodbye to Europe

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology research of BASF will leave the continent. The unit will move its headquarters from Limburgerhof in Germany to the U.S. The two research sites in Gatersleben, Germany, and Svaloev, Sweden, will be closed. In Limburgerhof the staff count will fall from 157 to 11. BASF founded the agricultural center in Limburgerhof in 1914 and has 11,000 square meters of greenhouses and about 40 hectares of fields. All in all, 140 European jobs will be lost, the company said. Furthermore, the development and commercialisation of products targeted solely at European markets will be cancelled. Genetically modified potato products will no longer be developed specifically for Europe, though the unit will continue seeking regulatory approval to “maintain all options,” the company said. The company cited the resistance to plant biotechnology from the majority of consumers, farmers and politicians in Europe pulled the trigger on the European sites. The plant-science unit will concentrate on the Americas and Asia, BASF said. A lot of jobs will move to the new headquarters in Raleigh, North Carolina. The only bright spot is that BASF said it will bolster its metabolite profiling subsidiary Metanomics GmbH in Berlin and biotech unit CropDesign in Ghent, Belgium. There are plans to expand the sites modestly, and a few of the jobs lost in Limburgerhof, Gatersleben and Svaloev will migrate there.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1983

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/basf-plant-science-says-goodbye-to-europe.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA74.95 CHF10.30%
  • BIOTEST80.50 EUR6.83%
  • WILEX2.22 EUR5.71%

FLOP

  • 4SC1.20 EUR-6.25%
  • VITA 343.78 EUR-2.83%
  • EPIGENOMICS3.12 EUR-2.50%

TOP

  • WILEX2.22 EUR177.5%
  • MAGFORCE6.50 EUR17.1%
  • SANTHERA74.95 CHF10.2%

FLOP

  • VITA 343.78 EUR-24.6%
  • MOLOGEN7.80 EUR-19.3%
  • PAION2.40 EUR-17.2%

TOP

  • SANTHERA74.95 CHF3647.5%
  • CO.DON2.50 EUR212.5%
  • PAION2.40 EUR182.4%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-67.7%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 19.08.2014


Current issue

All issues

Product of the week

Products